相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Review of safety and efficacy of approved systemic psoriasis therapies
Shivani B. Kaushik et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
April W. Armstrong et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Biologics and Psoriasis The Beat Goes On
Hee J. Kim et al.
DERMATOLOGIC CLINICS (2019)
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Jillian Frieder et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis
April W. Armstrong et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
Yahiya Y. Syed
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice
Steven R. Feldman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Clinical meaningfulness of complete skin clearance in psoriasis
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Treating psoriasis with adalimumab
Kenneth Gordon
Therapeutics and Clinical Risk Management (2016)
The global burden of psoriatic skin disease
K. L. Goff et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis
Hema N. Viswanathan et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Factors affecting response to biologic treatment in psoriasis
Jacek Karczewski et al.
DERMATOLOGIC THERAPY (2014)
Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody
Chris B. Russell et al.
JOURNAL OF IMMUNOLOGY (2014)
Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Genetic Epidemiology of Psoriasis
Rashmi Gupta et al.
CURRENT DERMATOLOGY REPORTS (2014)
Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States Findings From the National Psoriasis Foundation Surveys, 2003-2011
April W. Armstrong et al.
JAMA DERMATOLOGY (2013)
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France
A. Maza et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Dimensions of patient needs in dermatology: subscales of the patient benefit index
Christine Blome et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Conversations on psoriasis - what patients want and what physicians can provide: A qualitative look at patient and physician expectations
Elizabeth E. Uhlenhake et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2010)
Psoriasis: is the impairment to a patient's life cumulative?
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
USTEKINUMAB FOR THE TREATMENT OF PSORIASIS: REVIEW OF THREE MULTICENTER CLINICAL TRIALS
D. Farhi
DRUGS OF TODAY (2010)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results
M. K. A. Basra et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis
Dennis A. Revicki et al.
DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
分享论文
